# A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

> **NCT05679388** · PHASE1 · TERMINATED · sponsor: **University of Chicago** · enrollment: 60 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Metastatic
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Relugolix Pill
- **DRUG:** Ritonavir
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT05679388
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-13
- **Primary completion:** 2024-08-05
- **Final completion:** 2024-08-05
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Terminated by the PI
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05679388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05679388, "A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05679388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*